HERTFORDSHIRE, England and
PITTSBURGH, May 12, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ,
TASE: MYL) today announced the U.S. launch of Frovatriptan
Succinate Tablets 2.5 mg, a generic version of Endo's Frova®
Tablets. Mylan received final approval from the U.S. Food and Drug
Administration (FDA) for its Abbreviated New Drug Application
(ANDA) for this product, which is used to treat acute migraine
headaches in adults.
Frovatriptan Succinate Tablets 2.5 mg had U.S. sales of
approximately $88.3 million for the
12 months ending March 31, 2016,
according to IMS Health.
Currently, Mylan has 260 ANDAs pending FDA approval representing
$109.1 billion in annual brand sales,
according to IMS Health. Forty-seven of these pending ANDAs are
potential first-to-file opportunities, representing $37.5 billion in annual brand sales, for the 12
months ending December 31, 2015,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in approximately 165 countries and
territories. Our global R&D and manufacturing platform includes
more than 50 facilities, and we are one of the world's largest
producers of active pharmaceutical ingredients. Every member of our
nearly 35,000-strong workforce is dedicated to creating better
health for a better world, one person at a time. Learn more at
mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-frova-tablets-300267490.html
SOURCE Mylan N.V.